Insulet Corporation (PODD)
NMS · Healthcare · Medical Devices
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 706.3M | 783.8M | 761.7M | 801.7M |
| Gross Profit | 510.1M | 568.6M | 529.1M | 562.6M |
| Operating Income | 117.7M | 146.3M | 122.2M | 129.7M |
| Net Income | 87.6M | 101.6M | 91.1M | 95.0M |
| Diluted EPS | $1.24 | $1.44 | $1.30 | $1.37 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.3B | 1.7B | 2.1B | 2.7B |
| Gross Profit | 805.6M | 1.2B | 1.4B | 1.9B |
| Operating Income | 37.6M | 220.1M | 308.9M | 473.8M |
| Net Income | 4.6M | 206.3M | 418.3M | 247.1M |
| Diluted EPS | $0.07 | $2.94 | $5.78 | $3.48 |